Document Detail

Autologous serum eyedrops: literature review and implications for transfusion medicine specialists.
MedLine Citation:
PMID:  18410252     Owner:  NLM     Status:  MEDLINE    
Persistent corneal epithelial defects (CEDs) are caused by many diseases that are usually associated with decreased production of tears or reduced corneal sensitivity. Although surgical treatments are available for severe cases, CEDs are still difficult for ophthalmologists to treat. One treatment for CEDs that is uncommonly used in the United States is autologous serum eyedrops (ASEs). The first application of ASEs was described in 1984. This landmark report was followed by multiple studies that carefully evaluated the epithelial-promoting properties of ASEs and refined the means of ASE preparation. A number of clinical studies suggested the efficacy of ASEs in various ophthalmologic conditions. This article reviews the efficacy and complications of ASE use reported in these studies. Given that ophthalmologists may consult the blood bank to request ASEs, transfusion medicine physicians should be aware of the issues related to ASE preparation, storage, and potential utility.
Chisa Yamada; Karen E King; Paul M Ness
Publication Detail:
Type:  Journal Article; Review     Date:  2008-04-10
Journal Detail:
Title:  Transfusion     Volume:  48     ISSN:  0041-1132     ISO Abbreviation:  Transfusion     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-08-20     Completed Date:  2008-09-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417360     Medline TA:  Transfusion     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1245-55     Citation Subset:  IM    
Transfusion Medicine Division, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Autoantigens / therapeutic use*
Blood Transfusion*
Cornea / cytology,  physiology
Epithelium / physiology
Ophthalmic Solutions / pharmacology*,  therapeutic use
Reg. No./Substance:
0/Autoantigens; 0/Ophthalmic Solutions

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Auto-antibodies to receptor tyrosine kinases TrkA, TrkB and TrkC in patients with chronic Chagas' di...
Next Document:  Plasmapheresis in asparaginase-induced hypertriglyceridemia.